Pernix Therapeutics Holdings Inc

Pernix Therapeutics — Investor Presentation (September 2015)

27 slides from Pernix Therapeutics's investor presentation, Sep 29, 2015

  1. Slide 1: Executing the Plan

    Slide 1: Executing the Plan

  2. Slide 2: Safe Harbor Statement

    Slide 2: Safe Harbor Statement

    Safe Harbor Statement “safeharbor” 1995, You operations and inthe / 10-K for the year

  3. Slide 3: Investment Highlights

    Slide 3: Investment Highlights

    Investment Highlights > Rapidly growing specialty pharmaceutical company > Focused on pain & CNS markets > Dedicated 200-person specialty sales force, building 3 core brands > Proven, integrated commercial platform > Attractive pipeline of business development opportunities in target markets > Solid

  4. Slide 4: Building Momentum

    Slide 4: Building Momentum

    Building Momentum 32% NRx Growth since Mar ‘15 Significant momentum since Removal from ESI exclusion initiation of sampling list beginning 1/1/16; new Successful re-launch in Q2 2014 managed care contracts Treximet Zohydro ER sumatpfannaproren sodium cues eee D pounais

  5. Slide 5: Leveraging Expanded Rep Sales Force

    Slide 5: Leveraging Expanded Rep Sales Force

    Leveraging Expanded 200 Rep Sales Force Perix Sales Force (200) Pain Management Sales Force ‘ Neuroscience Sales Force Treximet / ZohydroER sami | sieAGK | oamtmtrane | \ “+ 4p dorepn tabiets } ZohyOIgER \ Treximet rocodone barat \ smn ngoen adam Pernix Prescriptions Direct

  6. Slide 6: Treximet Overview

    Slide 6: Treximet Overview

    Treximet Overview Tegxdmet Large Market Opportunity > Approved 2008, re-launched Sept. 2014 2014 > Acute treatment of migraine attacks with or » 14.8 million triptan Rx dispensed without aura > Treximet market share: 2% (by volume) * Adults + Pediatric patients aged 212 years 1% market share gain =

  7. Slide 7: Treximet TRx Turnaround

    Slide 7: Treximet TRx Turnaround

    Treximet TRx Turnaround kly TRx 6,000 + TRx up 18% since 5,500 5: sampling initiated at the end of March Samplesbecome avaateto +5000 S008, aaEe + NRx up 32% over same period * 4.500 + TRx dollars up 4,253 100% in 2015 4000 Remi Theapetesctoss we bara toreponen PPE LSS < re SPIE re eee ‘Source: Symp

  8. Slide 8: Treximet NRx On the Rise

    Slide 8: Treximet NRx On the Rise

    Treximet NRx On the Rise Treximet YOY Monthly Change in Branded NRx 20% 20% 5 10% i co ow 12% f Eth Sep th O14 Novt Dee t# dantS Feb1S MartS ApS Mayt5 Juris suk “Ags 2 2 0% & 20%

  9. Slide 9: Prescriber Activity Increasing

    Slide 9: Prescriber Activity Increasing

    Prescriber Activity Increasing sumagan apron sodium Monthly Prescriber Activity 14000 22 12,000 oe 20 10,000 H 1B 8,000 | a4 3 6,000, H é 14 i 4,000, 2,000 i ° 10 ‘Source: Symphony Health Source Pharmaceutcal Ault Suite (PHAST),

  10. Slide 10: Treximet market share versus competing triptans

    Slide 10: Treximet market share versus competing triptans

    10 95% 9.0% 8.0% ca 6.0% 40% se 20% 0.0% Jun-14 Jub14 Aug-14 Sep-14 Oct14 Now4 Dec-t4 Jan-18 Feb-15 Mar-I8 Apr-1S May-1 Jun-1S Jub15 Aug-15 Frova —Sumavel Dose Pro. —Zomig —CAMBIA. —Treximet 1) Relpax excluded. ‘Source: Symphony Health Source Pharmaceutical Ault Suite (PHAST), PERNIX.

  11. Slide 11: Managed Care Status

    Slide 11: Managed Care Status

    Managed Care Status eer August 2014 August 2015 Covered 16% Covered wasn 32% Preferred 31% Maintained Managed C rage for approximately 215 million lives Net Gover PERNIX.

  12. Slide 12: Extending Treximet Sales

    Slide 12: Extending Treximet Sales

    Extending Treximet Sales [scraticd 2018 2026 iwo generic competitors Additional generic may enter the market, as competitors may aresult of settlement. _enter the market, asa result of Pernix authorized generic C ) t ) ( } launches simultaneously Settlement Sep 2014 March 2015 April 2015, Re-launch

  13. Slide 13: Zohydro ER with BeadTek Overview

    Slide 13: Zohydro ER with BeadTek Overview

    Zohydro ER with BeadTek™ Overview «gions Zohydro ER with BeadTek™ Large Market Opportunity » Extended Release (ER) oral formulation of hydrocodone bitartrate designed with abuse- deterrent technology > Combination of IR/ER beads in a capsule > Launched 5/4/2015 > True 12-hour dosing allows more cons

  14. Slide 14: Zohydro ER Weekly TRx Trend

    Slide 14: Zohydro ER Weekly TRx Trend

    Zohydro ER Weekly TRx Trend + Recent managed care wins expected 11600 to drive growth 1400 + Removed from ESI exclusion list for + Submitted 30 managed care proposals covering 230m lives. EF PEPE IPS PLS PPEPO LES

  15. Slide 15: Zohydro ER Managed Care Status

    Slide 15: Zohydro ER Managed Care Status

    Zohydro ER Managed Care Status ‘Not Covered Not Covered ‘Seti 10% 21% sat Prelerred 10% Covered 45% Prefered 5% Coveres (PAST) sephcta 39% (PAST) jatus Through Recent Wins. stimate. Subject to PERNIXC

  16. Slide 16: Silenor Overview

    Slide 16: Silenor Overview

    Silenor Overview shenek enor + 4 coon bis Overv » Treats insomnia characterized by difficulties with sleep maintenance > Only non-controlled prescription sleep medication for people with trouble staying aslee| > Re-launched mid-2014 > Weekly TRx reached all-time high week ending 9/18/15 Large Market

  17. Slide 17: Silenor Weekly TRx

    Slide 17: Silenor Weekly TRx

    Silenor Weekly TRx silenor + TRxup 73% y-o-yin 20 g NRxup 77% y-o-yin 20 TRxS havetripled since 2.500 the beginning of 2014 TR Growth driven primarily + Formulary wins: SiverSerpt, Humana, Envision me D 17 Source: Symphony Health Source Pharmaceutcal Audit Suite (PHAST).

  18. Slide 18: Silenor Prescriber Growth

    Slide 18: Silenor Prescriber Growth

    Silenor Prescriber Growth Record High g cae a4 § 00 126 J 3 s000 100 ? ‘ be 5 3.000 10 # a 2,000 175 10 1900 168 160 ° PO O_O OO OO OO Ah sh ah gh gd ah gh ah Ah sd Dd © © © © © © FEM EMH FHF MH KEM EP Fes F Moh FEM MF pF mm Total Presciibers —e-TRuPresatber 18 Source; Symphony Heath Source Phomaceu

  19. Slide 19: Silenor Managed Care Status

    Slide 19: Silenor Managed Care Status

    Silenor Managed Care Status Not Covered 17% ‘Not Covered 19% Covered 1% Preferred 11% Prefered 19% Covered (Pasn) (PAST) 2% Enhanced Preferr e And Removed ns At Key Accounts PERNIXC

  20. Slide 20: Pernix Prescriptions Direct (PPD)

    Slide 20: Pernix Prescriptions Direct (PPD)

    Pernix Prescriptions Direct (PPD) + Enables script ownership from time it is written to when itis filled + Eliminates abandonment between physician and pharmacy, increasing script fulfillment and refills * 25% increase in fill rate in pilot cities * Opportunity to improve compliance / refills * Supp

  21. Slide 21: IP / Life Cycle Management

    Slide 21: IP / Life Cycle Management

    IP / Life Cycle Management Treximet sabia repoen sodum sileniek 4p even bless ZohydroER (trydrocadone itartrateyQ Includes pans for an atemate dose version of 020 a 3 4) Includes issued 096 patent for BeadTek with expiryin 2024,

  22. Slide 22: Financial Overview

    Slide 22: Financial Overview

    y Financial Overview _PERNIXG THERAPEUTICS

  23. Slide 23: Accelerating Financial Performance

    Slide 23: Accelerating Financial Performance

    Accelerating Financial Performance “August 2014: Acquired ‘CNS product Treximet fom GSk anwar 2012A 2013A 2014A mRevenue mM Adjusted EBITDA (a) eects mi point of 20156 guidance ot $170-$180m nt aes, 530-535 A. TOA [Aor 2015: Acquired) fom Zogen’e 2015E” PERNIX.

  24. Slide 24: Summary P&L

    Slide 24: Summary P&L

    Summary P&L Three Months En Treximet $255 $210 $38.5 y ‘ilenor 60 59 56 19 Zohydro ER 40 z g 2 Other 1s 70 o7 172 Net revenue 47.0 $33.9 $538 $19.1 Costof product sales Bs ua 148 10.0 Operating expenses 48.9 4au7 416 23.2 Loss from operations (15.6) (18.9) (26) (14)

  25. Slide 25: Financing Timeline

    Slide 25: Financing Timeline

    Financing Timeline > $465 million raised since new management joined in February 2014 > Significant interest rate reduction on two most recent financings $250.0 $220.0 $200.0 150.0 100.0 $50.0 met Amount Raised interest Rate PERNIXC

  26. Slide 26: Summary

    Slide 26: Summary

    Summary > Rapidly growing specialty pharmaceutical company focused on pain & CNS markets * 32% Treximent NRx growth since initiation of sampling in March 2015 * 62% growth in managed care coverage for Zohydro ER expected beginning Jan 2016 * 77% Silenor YoY NRx growth in Q2 2015 » Proven, integrated

  27. Slide 27: Thank You

    Slide 27: Thank You

    lars Thank You THERAPEUTICS

Source: SEC EDGAR · 8-K filed Sep 29, 2015

More decks from Pernix Therapeutics Holdings Inc